top of page

- May 7, 2019

ATXA is on a mission !

Recent Posts

NTP42 Demonstrates Key Cardioprotective Benefits in Newly-published Preclinical Findings

ATXA Therapeutics receives Funding through the European Innovation Council Accelerator Programme

ATXA Presentation at ERS International Congress 2022

bottom of page